Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Journal of Cardiology

• Publication date

  2002-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(02)02776-5PMID 12423711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased regional and transmyocardial dispersion of ventricular repolarization in end-stage renal disease.

  1999cited by this paper
• QT interval dispersion: dispersion of ventricular repolarization or dispersion of QT interval?

  1998cited by this paper
• Relation of left ventricular mass and QT dispersion in patients with systematic hypertension.

  1997cited by this paper
• QT dispersion and mortality after myocardial infarction.

  1995cited by this paper
• QT dispersion and components of the QT interval in ischaemia and infarction.

  1995cited by this paper
• QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias?

  1994cited by this paper
• Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease.

  1994cited by this paper
• QT dispersion and sudden unexpected death in chronic heart failure.

  1994cited by this paper
• QT prolongation in type 2 diabetes mellitus treated with glibenclamide.

  1994cited by this paper
• Measurement of the QT interval and the risk associated with QTc interval prolongation: a review.

  1993cited by this paper
• Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death.

  1993cited by this paper
• QT dispersion in sinus beats and ventricular extrasystoles in normal hearts.

  1992cited by this paper
• The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients.

  1992cited by this paper
• QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population

  1991cited by this paper
• QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.

  1990cited by this paper
• The antidiabetic sulfonylurea glibenclamide is a potent blocker of the ATP-modulated K+ channel in insulin secreting cells.

  1987cited by this paper
• Monophasic action potential mapping in human subjects with normal electrocardiograms: direct evidence for the genesis of the T wave.

  1987cited by this paper
• Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction.

  1985cited by this paper
• QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

  1978cited by this paper
• Right ventricular monophasic action potentials in patients with long QT syndrome.

  1978cited by this paper
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

  1970cited by this paper

• Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation.

  2026cites this paper
• Severe hypoglycemia and hypothermia in massive metformin overdose

  2025cites this paper
• Medication time of metformin and sulfonylureas and incidence of cardiovascular diseases and mortality in type 2 diabetes: a pooled cohort analysis

  2025cites this paper
• Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population‐Based Cohort Study

  2022cites this paper
• Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared to metformin: a population-based cohort study

  2022cites this paper
• Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.

  2022cites this paper
• The modifying effects of adiposity on the cardiovascular safety of sulphonylureas

  2021cites this paper
• Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin

  2021cites this paper
• Metformin Shortens Prolonged QT Interval in Diabetic Mice by Inhibiting L-Type Calcium Current: A Possible Therapeutic Approach

  2020cites this paper
• Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

  2020cites this paper
• Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial

  2020cites this paper
• Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability

  2020cites this paper
• Severe iatrogenic hypoglycaemia requiring medical assistance is associated with concurrent prolongation of the QTc interval.

  2020cites this paper
• Methylome-wide association study provides evidence of particulate matter air pollution-associated DNA methylation

  2019cites this paper
• Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study

  2019cites this paper
• Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia

  2018cites this paper
• Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

  2017cites this paper
• Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.

  2017cites this paper
• Metformin reduces urate nephropathy in experimental nephrolithiasis

  2017cites this paper
• Effect of sodium‐glucose co‐transporter‐2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes

  2017cites this paper
• Large-scale pharmacogenomic study of sulfonylureas and the QT, JT, and QRS intervals: CHARGE Pharmacogenomics Working Group

  2016cites this paper
• Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes

  2016cites this paper
• Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues

  2014cites this paper
• [The use of gliclazide in individualized sulfonylurea therapy].

  2014cites this paper
• Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?

  2014cites this paper
• Fine-Mapping and Initial Characterization of QT Interval Loci in African Americans

  2012cites this paper
• Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?

  2012cites this paper
• Endocrine therapies and QTc prolongation.

  2010cites this paper
• Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas

  2010cites this paper
• Il trattamento farmacologico del diabete di tipo 2 e la prevenzione cardiovascolare: cosa aggiunge liraglutide?

  2009cites this paper
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

  2009cites this paper
• Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

  2008cites this paper
• Consequences of cardiac myocyte-specific ablation of KATP channels in transgenic mice expressing dominant negative Kir6 subunits.

  2006cites this paper
• Inpatient management of diabetes and hyperglycemia.

  2004cites this paper
• Genetic disruption of Kir6.2, the pore-forming subunit of ATP-sensitive K+ channel, predisposes to catecholamine-induced ventricular dysrhythmia.

  2004cites this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cites this paper
• Review: Diabetes and the QT interval: time for debate

  2004cites this paper